flc powder  (Pfizer Inc)

Journal: The Journal of Clinical Investigation

Article Title: Dynamic ploidy changes drive fluconazole resistance in human cryptococcal meningitis

doi: 10.1172/JCI124516

Figure Lengend Snippet: In vitro experiments performed by inoculation of clinical strain into YPD with the addition of FLC with or without 5FC. Black line indicates total CFUs per milliliter at each sample time point. Red line indicates the heteroresistant subpopulation derived by CFUs per milliliter growing on YPD plus fluconazole. Data points with error bars represent the mean ± SEM of quadruplicated experiments. ( A ) Strain 1501 clinical data showing increased proportion of resistance. ( B ) Strain 1501 grown in YPD with the addition of 16 mg/l FLC. ( C ) Strain 1501 grown in YPD with the addition of 16 mg/l FLC and 16 mg/l 5FC. ( D ) Strain 1901 clinical data. ( E ) Strain 1901 grown in YPD with the addition of 16 mg/l FLU. ( F ) Strain 1901 grown in YPD with the addition of 16 mg/l FLC and 16 mg/l 5FC. This strain had acquired resistance to 5FC.

Article Snippet: Drug-containing plates were made by the addition of a stock solution of 50 mg/ml FLC powder (Alfa-Aesar) in DMSO, to final concentrations of 8, 16, 32, and 64 mg/l.

Techniques: In Vitro, Derivative Assay